Companies ›Healthcare ›SNWV.O

SNWV.O — NASDAQ Diversified Medical Equipment & Supplies

SANUWAVE Health Inc

$6,31

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

54,3M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

9,7 %

ROE

729,6 %

Net margin

26,8 %

Debt / equity

13,56

Beta

—

52w range

—

Volume

Day range

—

Prev close

$16,66

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

SANUWAVE Health Inc develops and commercializes medical devices for wound care and regenerative medicine, generating revenue primarily through product sales and licensing agreements.

Business. SANUWAVE Health Inc (SNWV.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. Headquartered in the United States, the company is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

Generated · model-assisted

Sell-side consensus

BUY2 analysts

2 buy0 hold0 sell

Avg 12m price target43,50

Analyst recommendations

2 analysts · consensus Buy

Buy2

Hold0

Sell0

12-month price target

43,50

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

2 analysts · indicative

Ownership→

UBS Financial Services, Inc.

largest disclosed fund holder

Profitability→

729,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning SNWV.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to SNWV.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

SANUWAVE Health Inc (SNWV.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. Headquartered in the United States, the company is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

AI synthesis

GENERATED

SANUWAVE Health Inc operates with a highly leveraged capital structure, as evidenced by a debt-to-equity ratio of 13.56, indicating significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.38, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of $10.97 million supports operational flexibility, though the negative net cash position after subtracting total debt raises concerns about long-term liquidity.

Profitability metrics show mixed performance. The company reports a net income of $11.81 million and a return on equity of 7.30%, but its return on assets of 0.32% is significantly below industry norms, indicating inefficient asset utilization. Gross profit of $33.97 million represents 77.1% of revenue, suggesting strong cost control in production, though operating income of $4.27 million reflects higher overhead costs.

Geographic and segment exposure is not disclosed in the available data, but the company's revenue concentration in a single product line (wound care devices) introduces operational risk. The absence of segment-specific revenue breakdowns limits visibility into diversification efforts.

Growth trajectory is constrained by the company's current financial position. While revenue of $44.05 million is reported, no specific growth rate is provided. Analysts project a mean price target of $43.50, implying a 156% upside from the current market price of $16.96, though this is based on limited data and no recent revenue growth figures.

Risk factors include high leverage and potential dilution, though the latter is assessed as low. The company's negative net cash position after debt subtraction raises liquidity concerns, and the absence of disclosed capital expenditure plans beyond the $1.94 million outflow suggests limited investment in future growth.

Recent events include the publication of the latest financial data in the market data source, but no specific filings or transcripts are cited in the available data. The company's reliance on a single product line and high debt levels remain key operational risks.

Key takeaways

The company's high debt-to-equity ratio (13.56) indicates significant financial leverage and potential liquidity risk.
Despite a strong gross margin (77.1%), the low return on assets (0.32%) suggests inefficient use of capital.
Analysts project a mean price target of $43.50, implying a 156% upside from the current market price.
The absence of segment-specific revenue data limits visibility into diversification and risk distribution.
The company's free cash flow of $10.97 million provides some operational flexibility but is offset by a negative net cash position after debt.
"margin_outlook_rationale": "Gross margin remains strong at 77.1%, but operating margin is constrained by high overhead costs.",

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$6,31

Market cap

$145.8M

Enterprise valueⓘ

$167.8M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

43.3x

P / Bⓘ

90.1x

P / Tangible bookⓘ

90.1x

Tangible book

$1.6M

Net cashⓘ

-$22.0M

Current ratioⓘ

1.4

Debt / equityⓘ

13.6

ROAⓘ

31.6%

ROEⓘ

7.3%

Cash conversionⓘ

33.0%

CapEx / revenueⓘ

-4.4%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Wound Care Products58,0 %

low · business_description · 2026-07-03

Wound Care Ultrasound Systems41,0 %

low · business_description · 2026-07-03

Business relationships

Business relationships3 disclosed relationships · 2 types · extracted from filings & disclosures

Suppliers2

Dynamic Holdings Ltd.0029.HKSupplier95%Source ↗

Nortech Systems IncNSYS.OSupplier95%Source ↗

Partners1

Celularity IncCELU.OPartner85%Source ↗

Supply chain

Vendors → SNWV ↔ Partners → Customers · click any node to drill

3 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

Peer comparison8 peers · vs SNWV · multiples and returns

ABT—

Abbott Laboratories

$107,13

187,2B USD

P/E

26,3x

+14,0 vs self

Div yield

2,4 %

— vs self

ROE

12,5 %

-717,1 vs self

MDT—

Medtronic PLC

$86,19

110,3B USD

P/E

21,4x

+9,0 vs self

Div yield

3,4 %

— vs self

ROE

9,7 %

-719,9 vs self

MDLN—

MEDLINE INC.

$40,47

53,2B USD

P/E

202,6x

+190,3 vs self

Div yield

—

— vs self

ROE

—

— vs self

SYK—

Stryker Corp

$341,20

131,8B USD

P/E

38,0x

+25,6 vs self

Div yield

—

— vs self

ROE

13,5 %

-716,1 vs self

BDX—

Becton Dickinson And Co

$170,21

48,4B USD

P/E

25,6x

+13,2 vs self

Div yield

2,8 %

— vs self

ROE

7,0 %

-722,7 vs self

HSIC—

Henry Schein Inc

$88,21

10,1B USD

P/E

80,5x

+68,2 vs self

Div yield

—

— vs self

ROE

3,0 %

-726,7 vs self

BAX—

Baxter International Inc

$28,10

14,5B USD

P/E

—

— vs self

Div yield

2,3 %

— vs self

ROE

-15,4 %

-745,1 vs self

SOLV—

SOLVENTUM CORPORATION

$76,83

13,3B USD

P/E

8,6x

-3,8 vs self

Div yield

—

— vs self

ROE

30,8 %

-698,8 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,39

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-15 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,39
Revenue	—no estimate	—no estimate	51,8M USD
Operating income	—no estimate	—no estimate	7,2M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution2 analysts

Strong buy0

Buy2

Hold0

Sell0

Strong sell0

12-month price target$43,50 · Median $43,50

Low $40,00High $47,00

Operating income · consensus7,2M USD

EPS surprise

+251,9 %

reported vs consensus · beat

Revenue surprise

−14,9 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$40,00

Mean$43,50

Median$43,50

High$47,00

Spot$6,31

+589.4 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin9,7 %Above median

Net Margin26,8 %Above P75

ROE729,6 %Best in class

Capex / Rev-4,4 %Bottom quartile

D/E13,56Bottom quartile

Cash Conv0,33Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 57 712 sh17 grants6 insiders

Blizard JeffreyDirector · Stock Option (right to buy) → Common StockAcquired 3 208 @ $17,29grant · 2026-03-31
Bazar Gregory MatthewDirector · Stock Option (right to buy) → Common StockAcquired 3 208 @ $17,29grant · 2026-03-31
Miller Ian D.Director · Stock Option (right to buy) → Common StockAcquired 3 609 @ $17,29grant · 2026-03-31
FRANK MORGAN C.Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 3 208 @ $17,29grant · 2026-03-31
Tyler JamesDirector · Stock Option (right to buy) → Common StockAcquired 3 208 @ $17,29grant · 2026-03-31
Wern David TimothyExec VP of Sales · Stock Option (right to buy) → Common StockAcquired 2 500 @ $26,96grant · 2026-01-30
FRANK MORGAN C.Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 24 000 @ $26,96grant · 2026-01-30
FRANK MORGAN C.Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 1 540 @ $29,84grant · 2025-12-31
Miller Ian D.Director · Stock Option (right to buy) → Common StockAcquired 1 733 @ $29,84grant · 2025-12-31
Tyler JamesDirector · Stock Option (right to buy) → Common StockAcquired 1 540 @ $29,84grant · 2025-12-31
Bazar Gregory MatthewDirector · Stock Option (right to buy) → Common StockAcquired 1 540 @ $29,84grant · 2025-12-31
Blizard JeffreyDirector · Stock Option (right to buy) → Common StockAcquired 1 540 @ $29,84grant · 2025-12-31
Bazar Gregory MatthewDirector · Stock Option (right to buy) → Common StockAcquired 1 342 @ $37,48grant · 2025-09-30
Miller Ian D.Director · Stock Option (right to buy) → Common StockAcquired 1 510 @ $37,48grant · 2025-09-30
Blizard JeffreyDirector · Stock Option (right to buy) → Common StockAcquired 1 342 @ $37,48grant · 2025-09-30
Tyler JamesDirector · Stock Option (right to buy) → Common StockAcquired 1 342 @ $37,48grant · 2025-09-30
FRANK MORGAN C.Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 1 342 @ $37,48grant · 2025-09-30

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Ev To Operating Cash Flow
enterprise_value / operating_cash_flow
Return On Equity
net_income / total_equity
Price To Earnings
market_price / (net_income / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)

Source documents

SANUWAVE Health Inc Market data — financials · 2026-05-29
SANUWAVE Health Inc Market data — analyst estimates · 2026-05-29

Ownership & reference

Top holders

UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$4M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$13M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$3M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$2M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

Morgan C. FrankChairman of the Board, Chief Executive Officer

Insider activity

Net selling1 buys · 17 sellsnet -$7,2M2 insiders · last 365d

Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 500 @ $16,11$8K · 2026-05-01
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 10 081 @ $16,11$162K · 2026-05-01
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 24 000 @ $16,15$388K · 2026-04-30
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 1 000 @ $16,15$16K · 2026-04-30
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 23 360 @ $17,25$403K · 2026-04-29
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 1 000 @ $17,25$17K · 2026-04-29
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 43 788 @ $18,47$809K · 2026-04-28
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 2 500 @ $18,47$46K · 2026-04-28
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 202 @ $20,50$4K · 2026-04-21
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 11 267 @ $20,46$231K · 2026-04-17
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 5 000 @ $20,46$102K · 2026-04-17
MANCHESTER MANAGEMENT CO LLCDirector by Deputization · Common Stock, par value $0.001Sold 6 500 @ $21,04$137K · 2025-12-12
MANCHESTER MANAGEMENT CO LLCDirector by Deputization · Common Stock, par value $0.001Sold 13 500 @ $31,28$422K · 2025-12-11
MANCHESTER MANAGEMENT CO LLCDirector by Deputization · Common Stock, par value $0.001Sold 8 625 @ $30,39$262K · 2025-12-10
MANCHESTER MANAGEMENT CO LLCDirector by Deputization · Common Stock, par value $0.001Sold 8 785 @ $30,58$269K · 2025-12-09
MANCHESTER MANAGEMENT CO LLCDirector by Deputization · Common Stock, par value $0.001Sold 125 400 @ $30,75$3,9M · 2025-12-08
MANCHESTER MANAGEMENT CO LLCDirector by Deputization · Common Stock, par value $0.001Sold 2 000 @ $31,60$63K · 2025-12-08
Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareBought 1 267 @ $30,28$38K · 2025-10-06

Short positioning

615.0Kshares short-2.5% vs prior

1.89days to cover

47.1%short of daily vol

29fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

SNWV.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSuppliersPartners

Evidence & claims

From filings & derived data

Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 16.8%Derived (calculated)
Net margin (FY 2025-12-31): 26.8%Derived (calculated)
Gross margin (FY 2025-12-31): 77.1%Derived (calculated)
Return on equity (FY 2025-12-31): 729.6%Derived (calculated)
Return on assets (FY 2025-12-31): 31.6%Derived (calculated)
Current ratio (FY 2025-12-31): 1.38xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 22.07xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 296.3%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 24.7%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 118.6%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 105.5%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 38.4%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2021-12-31): -16.6%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 135.7%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 57.9%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 28.5%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 101.0%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 35.0%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 110.3%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 24.0%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -22.2%Derived (calculated)
Gross profit (annual): USD 33.97MSEC XBRL filing
Operating income (annual): USD 4.95MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-16FILING8-K filing →

2026-06-15FILING8-K filing →

2026-05-12FILING8-K filing →

2026-05-12FILING10-Q filing →

2026-05-01 00:00 UTCINSIDER2 insider transactions — 2026-05 · net sell $170k

2026-05-01INSIDEROpaleye Management Inc. sold 500 sh Common Stock, par value $0.001 per share — 10% owner ~$8k

2026-05-01INSIDEROpaleye Management Inc. sold 10.1k sh Common Stock, par value $0.001 per share — 10% owner ~$162k

2026-04-30 00:00 UTCINSIDER9 insider transactions — 2026-04 · net sell $2.0M

2026-04-30INSIDEROpaleye Management Inc. sold 24.0k sh Common Stock, par value $0.001 per share — 10% owner ~$388k

2026-04-30INSIDEROpaleye Management Inc. sold 1.0k sh Common Stock, par value $0.001 per share — 10% owner ~$16k

2026-04-29FILINGDEF 14A filing →

2026-04-29INSIDEROpaleye Management Inc. sold 23.4k sh Common Stock, par value $0.001 per share — 10% owner ~$403k

2026-04-29INSIDEROpaleye Management Inc. sold 1.0k sh Common Stock, par value $0.001 per share — 10% owner ~$17k

2026-04-28INSIDEROpaleye Management Inc. sold 43.8k sh Common Stock, par value $0.001 per share — 10% owner ~$809k

2026-04-28INSIDEROpaleye Management Inc. sold 2.5k sh Common Stock, par value $0.001 per share — 10% owner ~$46k

2026-04-21INSIDEROpaleye Management Inc. sold 202 sh Common Stock, par value $0.001 per share — 10% owner ~$4k

2026-04-17INSIDEROpaleye Management Inc. sold 11.3k sh Common Stock, par value $0.001 per share — 10% owner ~$231k

2026-04-17INSIDEROpaleye Management Inc. sold 5.0k sh Common Stock, par value $0.001 per share — 10% owner ~$102k

2026-04-16FILING8-K filing →

2026-03-31 00:00 UTCINSIDER5 insider transactions — 2026-03 5 derivative

2026-03-31INSIDERBazar Gregory Matthew acquired 3.2k sh Stock Option (right to buy) — Director

2026-03-31INSIDERFRANK MORGAN C. acquired 3.2k sh Stock Option (right to buy) — Director, Chief Executive Officer

2026-03-31INSIDERTyler James acquired 3.2k sh Stock Option (right to buy) — Director

2026-03-31INSIDERMiller Ian D. acquired 3.6k sh Stock Option (right to buy) — Director

2026-03-31INSIDERBlizard Jeffrey acquired 3.2k sh Stock Option (right to buy) — Director

2026-03-26FILING8-K filing →

2026-03-26FILING10-K filing →

2026-03-13FILING8-K filing →

2026-01-30 00:00 UTCINSIDER2 insider transactions — 2026-01 2 derivative

2026-01-30INSIDERFRANK MORGAN C. acquired 24.0k sh Stock Option (right to buy) — Director, Chief Executive Officer

2026-01-30INSIDERWern David Timothy acquired 2.5k sh Stock Option (right to buy) — Exec VP of Sales

2025-12-31 00:00 UTCINSIDER5 insider transactions — 2025-12 5 derivative

2025-12-31INSIDERTyler James acquired 1.5k sh Stock Option (right to buy) — Director

2025-12-31INSIDERFRANK MORGAN C. acquired 1.5k sh Stock Option (right to buy) — Director, Chief Executive Officer

2025-12-31INSIDERBazar Gregory Matthew acquired 1.5k sh Stock Option (right to buy) — Director

2025-12-31INSIDERMiller Ian D. acquired 1.7k sh Stock Option (right to buy) — Director

Showing the 40 most recent of 59 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread